SLDB vs. ANIP, DYN, INDV, AMPH, ETNB, ADPT, EVO, SPRY, ARDX, and OCUL
Should you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), 89bio (ETNB), Adaptive Biotechnologies (ADPT), Evotec (EVO), ARS Pharmaceuticals (SPRY), Ardelyx (ARDX), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.
Solid Biosciences vs.
Solid Biosciences (NASDAQ:SLDB) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, community ranking, earnings and analyst recommendations.
In the previous week, ANI Pharmaceuticals had 4 more articles in the media than Solid Biosciences. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 2 mentions for Solid Biosciences. ANI Pharmaceuticals' average media sentiment score of 1.20 beat Solid Biosciences' score of 1.10 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.
Solid Biosciences has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Solid Biosciences' return on equity.
ANI Pharmaceuticals has higher revenue and earnings than Solid Biosciences. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.
81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 13.6% of Solid Biosciences shares are held by insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
ANI Pharmaceuticals received 164 more outperform votes than Solid Biosciences when rated by MarketBeat users. However, 69.27% of users gave Solid Biosciences an outperform vote while only 64.46% of users gave ANI Pharmaceuticals an outperform vote.
Solid Biosciences currently has a consensus price target of $15.67, indicating a potential upside of 258.50%. ANI Pharmaceuticals has a consensus price target of $79.75, indicating a potential upside of 16.66%. Given Solid Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Solid Biosciences is more favorable than ANI Pharmaceuticals.
Solid Biosciences has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
Summary
Solid Biosciences beats ANI Pharmaceuticals on 11 of the 19 factors compared between the two stocks.
Get Solid Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Solid Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:SLDB) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy SLDB Stock Free SLDB Stock Alerts